Advertisement

Picture Eurasanté BioFIT 2017 Strasbourg France November 600x60px
Document › Details

ThromboGenics N.V.. (3/24/16). "Press Release: ThromboGenics To Present at Key Investor Meetings". Leuven.

Organisations Organisation ThromboGenics N.V. (Euronext Brussels: THR)
  Group ThromboGenics (Group)
  Organisation 2 Kempen & Co. N.V.
  Group Van Lanschot (Group)
Products Product Jefferies 2016 Global Healthcare Conference New York
  Product 2 Kempen & Co Healthcare & Life Sciences Conference 2016 Amsterdam
Index terms Index term ThromboGenics–Société Générale: investor conference, 201606 supply service ThromboGenics presents at SG Healthcare & Biotechnology Conference 2016
  Index term 2 ThromboGenics–Leucadia: investor conference, 201606 supply service ThromboGenics presents at Jefferies Healthcare Conference in New York
Persons Person Piepers, Wouter (ThromboGenics 201303 Global Head Corporate Communications)
  Person 2 Berrebi, Sylvie (Huntsworth 201506 at Citigate Dewe Rogerson)
     


4 Drug Candidates: Novel Disease Modifying Treatments for Diabetic Eye Disease,

1 Drug Candidate: Innovative Orphan Drug for Treatment of Pediatric Cancer


ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative treatments for back of the eye disease, today announced that it will be presenting at several key investor meetings over the next few weeks and months.

> Kempen & Co 9th European Healthcare & Life Sciences Conference on April 6 – 7, 2016 in Amsterdam

> Invest Securities 10th European Smallcap Event on April 11 – 12, 2016 in Paris

> European Mid Small Cap Forum on May 18, 2016 in London

> ING Belgian Day on June 7 – 8, 2016 in New York City

> Jefferies 2016 Healthcare Conference on June 7 – 10, 2016 in New York City

> Société Générale Healthcare & Biotechnology Conference on June 28, 2016 in Paris

> European Mid Small Cap Forum on June 29 – 30, 2016 in Zurich


The announced roadshow plans follow the Company’s introduction of its new drug development pipeline first presented during last Friday’s ThromboGenics Research & Development Investor Meeting in London.

Over the past 18 months, ThromboGenics has developed a world class pipeline of disease modifying drug candidates for the treatment of diabetic eye disease. The pipeline consists of THR-409 (ocriplasmin), THR-317 (anti-PlGF), THR-149 (plasma kallikrein inhibitor), which has resulted from a research collaboration with Bicycle Therapeutics, and THR-687 (integrin receptor antagonist), which was recently in-licensed from Galapagos. With that, ThromboGenics will initiate several new clinical trials over the next 3-4 years, starting in 2016.

Next to its ambitious plans in ophthalmology, ThromboGenics is also progressing its commitments in oncology via its spin out Oncurious nv, an emerging oncology company focused on the development of innovative orphan drugs for the treatment of pediatric tumors. Last week’s announcement of the Oncurious partnership with NMTRC in the US, is a last step in the preparative work before initiating a Phase I/IIa clinical program with TB-403 for the treatment of medulloblastoma, a rare, life-threatening pediatric cancer. Further announcements are awaited.

Ends


For further information please contact:

ThromboGenics
Wouter Piepers,
Global Head of Corporate Communications & IR
+32 16 75 13 10 / +32 478 33 56 32
wouter.piepers@thrombogenics.com

Citigate Dewe Rogerson
Sylvie Berrebi, David Dible
Tel: +44 20 7282 2867 / +44 20 7282 1052
sylvie.berrebi@citigatedr.co.uk


About ThromboGenics

ThromboGenics is an integrated biopharmaceutical company focused on developing and commercializing innovative treatments for back of the eye disease, with a focus on diabetic eye disease.

Diabetic retinopathy (DR) and diabetic macular edema (DME) are the fastest growing segments of the overall ophthalmology market, which is forecast to increase in value from an estimated $1.6 billion in 2015 to $4.2 billion in 2023, or a 16% CAGR.

ThromboGenics pioneered the new drug category of pharmacological vitreolysis with Jetrea® (ocriplasmin). Jetrea® is now approved for the treatment of vitreomacular traction in over 54 countries worldwide. Alcon, a division of Novartis, commercializes Jetrea® outside the United States.

Recently, ThromboGenics initiated a Phase II clinical trial to assess ocriplasmin as a potential treatment for diabetic retinopathy.

ThromboGenics is headquartered in Leuven, Belgium, and is listed on the NYSE Euronext Brussels exchange under the symbol THR. More information is available at www.thrombogenics.com


Important information about forward-looking statements

Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties.
The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report.

This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of ThromboGenics in any jurisdiction. No securities of ThromboGenics may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

   
Record changed: 2017-07-02

Advertisement

Picture EBD Group BioPharm America 2017 BPA Boston MA Save USD100 600x60px

More documents for ThromboGenics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Berlin Partner HealthCapital BIO-Europe 2017 Germany November 600x60px




» top

Advertisements

Picture Berlin Partner HealthCapital BIO-Europe 2017 Germany November 120x240px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px 41 Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA Save USD100 120x180px Picture Berlin Partner HealthCapital BIO-Europe 2017 Germany November 120x240px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px 22 Picture EBD Group BioPharm America 2017 BPA Boston MA Save USD100 120x180px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px